| |
PRZOOM - /newswire/ -
Amherst, NH, United States, 2011/03/02 - Greystone Research analyzes commercial successes, pipeline candidates, proprietary SR formulation technologies and market prospects.
|
| |
Engineered formulations of injectable drugs – a class that includes established therapeutics for a number of disease segments including metabolic diseases, neurology and oncology – will experience an annual growth rate of 9.3 percent, exceeding $10 billion in market value by 2015, according to a new and comprehensive analysis by Greystone Research Associates. Growth will be spread across several major indications and will be driven in part by product candidates currently in the development pipeline.
“The technologies that are being used to create these extended release formulas include a range of approaches such as microsphere encapsulation, drug conjugation, and physical chemistry processing,” explains, George Perros, Greystone Managing Director. “The advantages of these drug products have allowed sustained release injectables to quietly carve out a healthy space for themselves in a number of therapeutic indications.”
This market segment relies on a collaborative business model, one that involves the IP owner, the drug developer, the device designer or manufacturer and quite often a CSO. Not surprisingly, partnerships and alliances are a hallmark of this segment.
Complete findings are contained in a new report researched and written by Greystone Research. Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens examines the current market and evolving potential for sustained release injectables. The report assesses the therapeutic impact of approved sustained release injectable drugs and development-stage candidates, and analyzes key market segments, technology factors, demand drivers and the competitive landscape.
About Greystone Research
Greystone Research Associates (greystoneassociates.org) is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
|
mksmith[.]greystoneassociates.org 
